Evidence map›Paper›PMID 30792230›Full record

ArticleThe Journal of cell biology2019

GLP-1 signaling suppresses menin's transcriptional block by phosphorylation in β cells.

Bowen Xing, Jian Ma, Zongzhe Jiang, Zijie Feng, Sunbin Ling, Katy Szigety, Wen Su, Longmei Zhang, Ruirui Jia, Yanmei Sun and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of cell biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Bowen XingShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China.ORCID 0000-0002-1244-8545
Jian MaDepartment of Cancer Biology, Abramson Family Cancer Research Institute, Institute of Diabetes, Obesity, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0002-4963-304X
Zongzhe JiangShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China.
Zijie FengDepartment of Cancer Biology, Abramson Family Cancer Research Institute, Institute of Diabetes, Obesity, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Sunbin LingDepartment of Cancer Biology, Abramson Family Cancer Research Institute, Institute of Diabetes, Obesity, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Katy SzigetyDepartment of Cancer Biology, Abramson Family Cancer Research Institute, Institute of Diabetes, Obesity, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0001-9754-6381
Wen SuShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China.
Longmei ZhangShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China.
Ruirui JiaShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China.
Yanmei SunShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China.
Lin ZhangShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China.
Xiangchen KongShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China.ORCID 0000-0001-5149-1987
Xiaosong MaShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China xsm@szu.edu.cn.
Xianxin HuaShenzhen University, College of Medicine, Medical Center and Diabetes Center, Shenzhen, China huax@pennmedicine.upenn.edu.ORCID 0000-0003-4862-4691
Shenzhen University Health Science Center · CNCancer Research Institute · US

Funding

Beta Cell Regeneration by an Epigenetic PathwayR01DK097555 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HUA, XIANXIN · 2013 to 2016
$1.4M
NIDDK NIH HHS R01 DK097555
6 · The paper itself

Abstract

Both menin and glucagon-like peptide 1 (GLP-1) pathways play central yet opposing role in regulating β cell function, with menin suppressing, and GLP-1 promoting, β cell function. However, little is known as to whether or how GLP-1 pathway represses menin function. Here, we show that GLP-1 signaling-activated protein kinase A (PKA) directly phosphorylates menin at the serine 487 residue, relieving menin-mediated suppression of insulin expression and cell proliferation. Mechanistically, Ser487-phosphorylated menin gains increased binding affinity to nuclear actin/myosin IIa proteins and gets sequestrated from the

Indexed as

Signal TransductionTranscriptional ActivationTranscription, GeneticAnimalsCyclic AMP-Dependent Protein KinasesGlucagon-Like Peptide 1HEK293 CellsHumansInsulin-Secreting CellsMethyltransferasesMiceRatsRats, WistarRepressor ProteinsTranscription FactorsCyclic AMP-Dependent Protein KinasesGlucagon-Like Peptide 1Men1 protein, ratMethyltransferasesRepressor ProteinsSuv39h1 protein, ratTranscription Factors

Identifiers

PMID30792230
PMCPMC6400573
OpenAlexW2916242899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.